ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity

Francesca Pignataro 1, Antonina Minniti 1, Wanda Maglione 1, Francesco Campanaro 1, Domenico Sambataro 2, Gianluca Sambataro 2, Claudio Vitali 3 and Nicoletta Del Papa1, 1UOC Day Hospital Reumatologia, ASST Gaetano Pini, Milan, Italy, 2Istituto ArtroReuma, Catania, Italy, 3Sezione di Reumatologia, Istituto San Giuseppe, Como, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: nailfold capillaroscopy and Disease Activity, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously demonstrated that NEMO score, i.e., the cumulative number of microhaemorrhages (MHEs) and microthrombosis (MTs) observed in nailfold videocapillaroscopy (NVC), was a good indicator of the steady state level of disease activity (DA) in patients with SSc when the European Scleroderma Study Group (EScSG) index was taken as gold standard.
Aim of the study. To verify whether the NEMO score could be (i) a valid tool to assess DA, even when the modified European Scleroderma Trials and Research (EUSTAR) index was considered as comparator; (ii) a sensitive method to capture the overtime changes of DA.

Methods: NEMO score, EScSG and EUSTAR indices were assessed at baseline (T0) and after a follow up of 6-12 months (T1) in a cohort of 98 patients affected by SSc according to ACR/EULAR 2013 criteria (48 with limited and 50 with diffuse SSc). It was preliminarily established that at least 50% of SSc patients should be active at enrolment time (score ≥3, according to the EScSG DA index). The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was calculated to measure the sensitivity and specificity of NEMO score in classifying patients with predefined level of DA ( ≥ 3.0 and ≥ 2.5 scores for EScSG and EUSTAR indices, respectively). To assess overtime changes of DA, the differences (Δ) between T0 and T1 values of NEMO score, EScSG and EUSTAR indices were calculated and compared to each other.

Results: NEMO score values were very closely correlated with the corresponding values of both EScSG and EUSTAR indices at T0 and T1 observations [p< 0.0001 in all cases with the exception of the correlation with EScSG values at T1 (p< 0.03)]. Values of the two composite DA indices were also strictly related to each other either at T0 or T1 observations (p< 0.0001). NEMO score showed a very good performance in classifying patients with predefined level of DA. AUCs of ROC curve analysis were 0.91 and 0.88 considering the respective predefined levels of EScSG and EUSTAR indices as standard measures of significant levels of DA (p< 0.0001 in both cases). Δ values of NEMO score were significantly correlated with the corresponding values of both EScSG and EUSTAR indices. Weighted Cohen’s k level of agreement between Δ values of NEMO score and those of EScSG and EUSTAR indices was moderate (0.55 and 0.60, respectively), but close to the level of good agreement ( >0.60).

Conclusion: NEMO score confirms to be a feasible, non-invasive and valid tool to assess steady state levels and overtime changes of DA in patients with SSc. Thus, this NVC evaluation can represent an alternative or complementary method to measure this disease status entity in this disorder.


Disclosure: F. Pignataro, None; A. Minniti, None; W. Maglione, None; F. Campanaro, None; D. Sambataro, None; G. Sambataro, None; C. Vitali, None; N. Del Papa, None.

To cite this abstract in AMA style:

Pignataro F, Minniti A, Maglione W, Campanaro F, Sambataro D, Sambataro G, Vitali C, Del Papa N. NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/nemo-score-in-nailfold-videocapillaroscopy-is-a-good-tool-to-assess-both-steady-state-levels-and-overtime-changes-of-disease-activity-in-patients-with-systemic-sclerosis-a-comparison-with-both-the-co/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nemo-score-in-nailfold-videocapillaroscopy-is-a-good-tool-to-assess-both-steady-state-levels-and-overtime-changes-of-disease-activity-in-patients-with-systemic-sclerosis-a-comparison-with-both-the-co/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology